{
  "docId": "019de074-ad31-7288-aa0c-b4a964d6a9af",
  "docSlug": "31aafddb38d645745d1c40d83b8ae135",
  "documentTitle": "ATAI | Investor Presentation Deck | 30 slides",
  "authorId": "atai",
  "authorName": "atai",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 30,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes a quote from Keith Nuechterlein, Ph.D. regarding the clinical significance of the Symbol Coding results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ad31-7288-aa0c-b4a964d6a9af/9",
  "deckHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af",
  "deckJsonHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af.json",
  "deckAnchorHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.58,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "chart",
      "text": "PHASE 2 PoM TRIAL - EFFICACY DATA ON SUB-COMPONENTS OF MATRICS SCALE",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea79bc61-72d2-4b7b-8e05-c8d2e5f9933e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.32,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "list",
      "text": "OWNERSHIP: 51.9%\nPRODUCT: (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt oral capsules (RL-007)\nPHARMACOLOGY: GABA/nicotinic modulator\nPRODUCT FEATURES: Pro-cognitive effects demonstrated in two Phase 1 and two Phase 2 trials. No drug-related serious adverse events in over 500 study subject exposures\nINDICATIONS: Primary: Cognitive Impairment Associated with Schizophrenia (CIAS). Potential: Autism, Alzheimer's dementia\nCURRENT STATUS: Phase 2a biomarker trial completed in H2'21. Phase 2b FPI in 1Q'23. Phase 2b PoC data expected H2'24\nINTELLECTUAL PROPERTY: Issued composition of matter, formulation and method of use patents",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10c014e7-53f9-4138-835b-17d946bab9e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.58,
        "x": 0.38,
        "y": 0.19
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "656d2fa1-64d5-475a-92aa-1ac882a39a80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.38,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; HVLT = Hopkins Verbal Learning Test; TID = 3x/day dosing; PoC = Proof of Concept, PoM = Proof of Mechanism. 1. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of September 30th, 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6df70f6-80d9-4320-aab2-6308fb4c2522",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.22,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY: RL-007",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a22774b-0493-49c9-997e-3edb20616da6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "7712450c-2d52-4158-ab49-c501275e7758",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 8-9 present the problem statement for CIAS and anxiety disorders",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 24,
      "from": 9,
      "beatId": "ac5e080c-b74d-4115-a83a-25ce54f0c50b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 9-24 present traction data for various programs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fb6c66f9-d6d2-4897-9f7b-06bc8c0c19e3",
      "evidence": "Slides 8-9 present the problem statement and highlight the need for innovation",
      "position": 0,
      "objective": "Highlight the need for innovation in mental health treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8a640552-7d64-4f46-af4c-8041a39da251",
      "evidence": "The deck presents a clear and compelling vision for ATAI's mission and solution",
      "position": 1,
      "objective": "Present a compelling vision for ATAI's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}